LPTX - Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
- Leap Therapeutics press release ( NASDAQ: LPTX ): Q2 GAAP EPS of -$0.15 misses by $0.05 .
- Cash and cash equivalents totaled $90.9 million at June 30, 2022, expected to provide financial runway to mid-2024
- Shares +1.54% PM.
For further details see:
Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05